ASH 2022 Conference Coverage
Y

ASH 2022 Results From the Phase 2 OUTREACH Study: Lisocabtagene Maraleucel Administered as Outpatient/Inpatient Treatment in the Community/Non-University Setting in Patients With R/R LBCL

By ASH 2022 Conference Coverage FEATURING Yuliya Linhares
By ASH 2022 Conference Coverage FEATURING Yuliya Linhares
30 views
April 3, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Recommended

16:57

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

1.2K views

·

5 months ago
22:11

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

549 views

·

4 months ago
13:07

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

821 views

·

8 months ago
27:47

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

656 views

·

6 months ago
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

418 views

·

1 month ago
16:34

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

613 views

·

6 months ago
35:27

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

699 views

·

8 months ago
20:34

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

328 views

·

3 months ago
10:04

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

477 views

·

8 months ago
20:18

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

505 views

·

9 months ago
45:27

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

263 views

·

2 months ago
08:23

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

214 views

·

8 months ago
09:18

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized …

Insights from 2023 ASCO® Annual Meeting

J. Westin

1.5K views

·

1 year ago
30:07

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

325 views

·

5 months ago
29:26

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

304 views

·

5 months ago
06:07

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

174 views

·

1 month ago
28:33

The Truth About Current Consensus Statements on Hematopoietic Cell T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

509 views

·

9 months ago
35:24

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

395 views

·

7 months ago
33:48

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

428 views

·

7 months ago
17:07

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

282 views

·

5 months ago
AUTOPLAY